Bonraybio CoTPE:6955 65 EBITDA Margin % is 41.27% as of Dec. 2025, which is 145% above its 10-year median of 16.82. GuruFocus rates TPE:6955 with a GF Score™ of 65/100 and a GF Value™ of NT$184.74 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Bonraybio Co ranks better than 95.46% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bonraybio Co's EBITDA for the
three
months ended in Dec. 2025 was NT$33.9 Mil. Bonraybio Co's Revenue for the
three
months ended in Dec. 2025 was NT$82.2 Mil. Therefore, Bonraybio Co's EBITDA margin for the quarter that ended in Dec. 2025 was 41.27%.
Bonraybio Co (TPE:6955) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bonraybio Co EBITDA Margin % Related Terms
Bonraybio Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bonraybio Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6955 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Bonraybio Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonraybio Co (TPE:6955) has a EBITDA Margin % of 41.27% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bonraybio Co and its competitors. This is 145% above median its historical median of 16.82. According to the industry distribution chart, Bonraybio Co ranks #37 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 4.5%.
Is Bonraybio Co's EBITDA Margin % too high?
Bonraybio Co's current EBITDA Margin % of 41.27% is 145% above median its 10-year median of 16.82. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Bonraybio Co's value of 41.27% is 452.5% above this industry median. Based on the distribution chart, Bonraybio Co ranks #37 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonraybio Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #37 out of 815 companies for EBITDA Margin %. This places Bonraybio Co in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Bonraybio Co's value of 41.27% is 452.5% above this benchmark. While the company's 10-year median is 16.82 vs. the industry median of 7.47, Bonraybio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonraybio Co's current EBITDA Margin % of 41.27% is 452.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bonraybio Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current EBITDA Margin % is 41.27%, which is 145% above median its own 10-year median of 16.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$184.74, compared to a current price of NT$120.50 — trading 34.8% below its estimated fair value. The current EBITDA Margin % is 41.27%, which is 145% above median its 10-year median of 16.82 and 452.5% above the Medical Devices & Instruments industry median of 7.47. Bonraybio Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current EBITDA Margin % is 41.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$120.50 is trading 34.8% below its estimated GF Value™ of NT$184.74.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
EBITDA Margin %: 41.27% (145% above median its 10-year median of 16.82)
GF Value™: NT$184.74 vs. price of NT$120.50 (34.8% below fair value)
Industry Position: 452.5% above the Medical Devices & Instruments median (#37 of 815)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
65GF Score
Get the complete analysis for TPE:6955
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
